multiple myeloma - 1st line (L1) | |
multiple myeloma - 1st line (L1) | |
pembrolizumab based treatment | |
pembrolizumab plus lenalidomide and dexamethasone | KEYNOTE-185 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -